{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 5"],"alternate_symbols":["EIEE5"],"attribute_content":[],"medgen_id":"C3150731","symbol":"DEE5","name":"Early infantile epileptic encephalopathy 5","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013277\"}","{\"db\":\"OMIM\",\"id\":\"613477\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3451\"}","{\"db\":\"OMIM\",\"id\":\"182810.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 5\"}","{\"db\":\"OMIM\",\"id\":\"182810.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 5\"}","{\"db\":\"OMIM\",\"id\":\"182810.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 5\"}","{\"db\":\"OMIM\",\"id\":\"182810.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 5\"}","{\"db\":\"OMIM\",\"id\":\"613477\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 5\"}","{\"db\":\"OMIM\",\"id\":\"613477\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+5/8344\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613477\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"6755"}
{"type":"Disease","alternate_names":["JAMUAR SYNDROME"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"CN263317","symbol":"DEE84","name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 84","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032918\"}","{\"db\":\"OMIM\",\"id\":\"618792\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618792\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"JAMUAR SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"603370.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603370.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603370.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603370.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603370.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603370.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603370.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618792\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618792\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"43698"}
{"type":"Disease","alternate_names":[],"alternate_symbols":[],"attribute_content":[],"medgen_id":"CN279279","symbol":"ARCI","name":"Autosomal recessive congenital ichthyosis","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0017265\"}","{\"db\":\"OMIM\",\"id\":\"PS242300\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"281097\"}","{\"db\":\"NCBI for submitter\",\"id\":\"77759795\",\"ref_field\":\"name\"}"],"id":"42475"}
{"type":"Disease","alternate_names":["INFANTILE SPASM SYNDROME, X-LINKED 2"],"alternate_symbols":["EIEE2","ISSX2"],"attribute_content":[],"medgen_id":"C4750718","symbol":"DEE2","name":"Early infantile epileptic encephalopathy 2","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010396\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1934\"}","{\"db\":\"Orphanet\",\"id\":\"3451\"}","{\"db\":\"Orphanet\",\"id\":\"505652\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFANTILE SPASM SYNDROME, X-LINKED 2\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE2\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ISSX2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+2/8342\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"2108"}
{"type":"Disease","alternate_names":["Mental retardation"],"alternate_symbols":["MR"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"AAN/CNS, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21956720\",\"@Source\":\"PubMed\"}}}","medgen_id":"C0025362","name":"Intellectual functioning disability","keywords":[],"xrefs":["{\"db\":\"SNOMED CT\",\"id\":\"91138005\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental retardation\"}","{\"db\":\"SNOMED CT\",\"id\":\"228156007\",\"ref_field\":\"name\"}"],"id":"16665"}
{"type":"Disease","alternate_names":[],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C2986382","name":"Variant of unknown significance","keywords":[],"xrefs":[],"id":"11364"}
{"type":"Finding","alternate_names":["Birthmark","Cafe-au-lait macule","Cafe-au-lait macules","Cafe-au-lait spots","Café au Lait"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C0221263","name":"Cafe-au-lait spot","keywords":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000957\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005601\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007454\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Birthmark\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cafe-au-lait macule\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cafe-au-lait macules\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000957\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cafe-au-lait spots\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000957\",\"ref_field\":\"name\"}"],"id":"18088"}
{"type":"Disease","alternate_names":["GM3 SYNTHASE DEFICIENCY","SALT AND PEPPER MENTAL RETARDATION SYNDROME"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C1836824","symbol":"SPDRS","name":"Salt and pepper developmental regression syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012189\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171714\"}","{\"db\":\"Orphanet\",\"id\":\"370933\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GM3 SYNTHASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SALT AND PEPPER MENTAL RETARDATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"292"}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 82","GLUTAMATE OXALOACETATE TRANSAMINASE, MITOCHONDRIAL, DEFICIENCY OF","GOT2 DEFICIENCY"],"alternate_symbols":["EIEE82"],"attribute_content":[],"medgen_id":"C5231473","symbol":"DEE82","name":"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 82","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032880\"}","{\"db\":\"OMIM\",\"id\":\"618721\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"138150.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 82\"}","{\"db\":\"OMIM\",\"id\":\"138150.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 82\"}","{\"db\":\"OMIM\",\"id\":\"138150.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 82\"}","{\"db\":\"OMIM\",\"id\":\"138150.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 82\"}","{\"db\":\"OMIM\",\"id\":\"618721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 82\"}","{\"db\":\"OMIM\",\"id\":\"618721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLUTAMATE OXALOACETATE TRANSAMINASE, MITOCHONDRIAL, DEFICIENCY OF\"}","{\"db\":\"OMIM\",\"id\":\"618721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOT2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"618721\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"43192"}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 8","HYPEREKPLEXIA AND EPILEPSY"],"alternate_symbols":["EIEE8"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301437\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1260\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1845102","symbol":"DEE8","name":"Early infantile epileptic encephalopathy 8","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010375\"}","{\"db\":\"OMIM\",\"id\":\"300607\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"163985\"}","{\"db\":\"Orphanet\",\"id\":\"2076\"}","{\"db\":\"OMIM\",\"id\":\"300429.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 8\"}","{\"db\":\"OMIM\",\"id\":\"300429.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 8\"}","{\"db\":\"OMIM\",\"id\":\"300607\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 8\"}","{\"db\":\"OMIM\",\"id\":\"300607\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPEREKPLEXIA AND EPILEPSY\"}","{\"db\":\"OMIM\",\"id\":\"300607\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE8\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+8/8346\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300607\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"2176"}
{"type":"Disease","alternate_names":[],"alternate_symbols":["ARNSHL"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1846647","name":"Deafness, autosomal recessive","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019588\"}","{\"db\":\"OMIM\",\"id\":\"607197\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90635\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1710\",\"ref_field\":\"gard_id\"}"],"id":"10245","gard_id":"1710"}
{"type":"Disease","alternate_names":["Neoplasm of the ovaries","Neoplasm of the ovary","OVARIAN CANCER, SOMATIC","Ovarian neoplasia","Ovarian neoplasm","Ovarian tumor"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"NACB, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19042984\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"USPSTF, 2012\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"22964825\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23188549\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0919267","name":"Neoplasm of ovary","keywords":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100615\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"167000\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100615\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neoplasm of the ovaries\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100615\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neoplasm of the ovary\"}","{\"db\":\"OMIM\",\"id\":\"116806.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"164730.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"164870.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"192090.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"600098.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"600632.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"602544.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, SOMATIC\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100615\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ovarian neoplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100615\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ovarian neoplasm\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100615\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ovarian tumor\"}","{\"db\":\"SNOMED CT\",\"id\":\"123843001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ovarian tumor\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neoplasm+of+ovary/8972\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"123843001\",\"ref_field\":\"name\"}"],"id":"5713"}
{"type":"Disease","alternate_names":["CRANIOFACIAL DEFECTS, DYSMORPHIC EARS, STRUCTURAL BRAIN ABNORMALITIES, EXPRESSIVE LANGUAGE DELAY, AND IMPAIRED INTELLECTUAL DEVELOPMENT","MTOR-related hypomelanosis of Ito with neurodevelopmental abnormalities"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"CN263278","symbol":"CEBALID","name":"CEBALID syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032908\"}","{\"db\":\"OMIM\",\"id\":\"618774\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618774\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRANIOFACIAL DEFECTS, DYSMORPHIC EARS, STRUCTURAL BRAIN ABNORMALITIES, EXPRESSIVE LANGUAGE DELAY, AND IMPAIRED INTELLECTUAL DEVELOPMENT\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0032908\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618774\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"43636"}
{"type":"Disease","alternate_names":["Low sperm count","Oligozoospermia"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C0028960","name":"Oligospermia","keywords":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000798\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0001913\"}","{\"db\":\"MeSH\",\"id\":\"D009845\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Low sperm count\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000798\",\"ref_field\":\"name\"}"],"id":"34555"}
{"type":"Disease","alternate_names":["OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY"],"alternate_symbols":["DOA+"],"attribute_content":[],"medgen_id":"C3276549","name":"Autosomal dominant optic atrophy plus syndrome","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"125250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1215\"}","{\"db\":\"OMIM\",\"id\":\"125250\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"605290.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"125250\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DOA+\"}","{\"db\":\"Orphanet\",\"id\":\"1215\",\"ref_field\":\"name\"}"],"id":"3314"}
{"type":"Disease","alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 81"],"alternate_symbols":["EIEE81"],"attribute_content":[],"medgen_id":"C5231450","symbol":"DEE81","name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 81","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032858\"}","{\"db\":\"OMIM\",\"id\":\"618663\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618663\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 81\"}","{\"db\":\"OMIM\",\"id\":\"618663\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE81\"}","{\"db\":\"OMIM\",\"id\":\"612186.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612186.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612186.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612186.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612186.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618663\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618663\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"43090"}
{"type":"Disease","alternate_names":["Deafness 3 conductive with stapes fixation","Deafness conductive with stapes fixation","Deafness mixed with perilymphatic gusher","Dfn 3 nonsyndromic hearing loss and deafness","Gusher syndrome","Nance deafness","Perilymphatic Gusher-deafness syndrome","Sensorineural deafness, profound, with or without a conductive component, associated with a unique developmental abnormality of the ear"],"alternate_symbols":["DFN3"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24651602\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C1844678","symbol":"DFNX2","name":"Deafness, X-linked 2","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"304400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"383\"}","{\"db\":\"OMIM\",\"id\":\"304400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DFN3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+X-Linked+2/2161\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"304400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4932"}
{"type":"Disease","alternate_names":[],"alternate_symbols":[],"attribute_content":[],"medgen_id":"CN071292","name":"CFH-Related Dense Deposit Disease / Membranoproliferative Glomerulonephritis Type II","keywords":[],"xrefs":["{\"db\":\"GeneTests\",\"id\":\"299433\",\"ref_field\":\"name\"}"],"id":"12630"}
{"type":"Disease","alternate_names":["Chondrodystrophy with sensorineural deafness","Insley-Astley syndrome","Nance Sweeney chondrodysplasia","Nance-Insley syndrome"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"CN034493","symbol":"OSMEDB","name":"Otospondylomegaepiphyseal dysplasia, autosomal recessive","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0044206\"}","{\"db\":\"OMIM\",\"id\":\"215150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1427\"}","{\"db\":\"OMIM\",\"id\":\"215150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"5711"}
{"type":"Disease","alternate_names":[],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C5193138","symbol":"ODLURO","name":"O'Donnell-Luria-Rodan syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032793\"}","{\"db\":\"OMIM\",\"id\":\"618512\",\"type\":\"MIM\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0032793\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618512\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"42272"}
{"type":"Disease","alternate_names":[],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C4551527","symbol":"FSGS1","name":"Focal segmental glomerulosclerosis 1","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011303\"}","{\"db\":\"OMIM\",\"id\":\"603278\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"656\"}","{\"db\":\"Orphanet\",\"id\":\"93213\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Focal+Segmental+Glomerulosclerosis/2890\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603278\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"1293"}
{"type":"Disease","alternate_names":["WIP DEFICIENCY","WIPF1 DEFICIENCY"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C3281001","symbol":"WAS2","name":"Wiskott-Aldrich syndrome 2","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013779\"}","{\"db\":\"OMIM\",\"id\":\"614493\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"906\"}","{\"db\":\"OMIM\",\"id\":\"614493\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WIP DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"614493\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WIPF1 DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"WISKOTT-ALDRICH+SYNDROME+2/9478\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614493\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"16832"}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 52"],"alternate_symbols":["EIEE52"],"attribute_content":[],"medgen_id":"C4479236","symbol":"DEE52","name":"Epileptic encephalopathy, early infantile, 52","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0033361\"}","{\"db\":\"OMIM\",\"id\":\"617350\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"600235.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 52\"}","{\"db\":\"OMIM\",\"id\":\"600235.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 52\"}","{\"db\":\"OMIM\",\"id\":\"600235.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 52\"}","{\"db\":\"OMIM\",\"id\":\"600235.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 52\"}","{\"db\":\"OMIM\",\"id\":\"617350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 52\"}","{\"db\":\"OMIM\",\"id\":\"617350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE52\"}","{\"db\":\"OMIM\",\"id\":\"617350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"36944"}
{"type":"Disease","alternate_names":["Athabaskan brainstem dysgenesis","Athabaskan brainstem dysgenesis syndrome","Bosley Salih Alorainy syndrome","Navajo brainstem syndrome"],"alternate_symbols":["BSAS"],"attribute_content":[],"medgen_id":"C1832215","symbol":"ABDS","name":"Human HOXA1 syndromes","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011099\"}","{\"db\":\"OMIM\",\"id\":\"601536\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"69737\"}","{\"db\":\"Orphanet\",\"id\":\"69739\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Athabaskan+Brainstem+Dysgenesis/643\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Athabaskan brainstem dysgenesis\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011099\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Athabaskan brainstem dysgenesis syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8333\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011099\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601536\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4636","gard_id":"8333"}
{"type":"Disease","alternate_names":["Acute lymphoblastic leukemia, childhood","Acute lymphocytic leukemia","Leukemia, acute lymphoblastic, somatic"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C0023449","symbol":"ALL","name":"Acute lymphoid leukemia","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"613065\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"513\"}","{\"db\":\"SNOMED CT\",\"id\":\"128822004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Acute lymphocytic leukemia\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Acute+Lymphoblastic+Leukemia/188\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"91857003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613065\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"6569"}
{"type":"Finding","alternate_names":["Cardiac disease","Heart Diseases"],"alternate_symbols":[],"attribute_content":[],"medgen_id":"C0018799","name":"Heart disease","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0005267\"}","{\"db\":\"Centre for Mendelian Genomics,University Medical Centre Ljubljana\",\"id\":\"CMGVARID00287\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cardiac disease\"}"],"id":"17731"}
{"type":"Disease","alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 86"],"alternate_symbols":["EIEE86"],"attribute_content":[],"medgen_id":"CN282591","symbol":"DEE86","name":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 86","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618910\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618910\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 86\"}","{\"db\":\"OMIM\",\"id\":\"618910\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE86\"}","{\"db\":\"OMIM\",\"id\":\"618910\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618910\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"53475"}
{"type":"Disease","alternate_names":["Hepatocellular cancer","Hepatocellular carcinoma, adult","Hepatoma","Increased hepatocellular carcinoma risk","Increased incidence of hepatocellular carcinoma","LIVER CELL CARCINOMA","Liver cancer","Liver cancer adult","Liver cell carcinoma adult","Primary carcinoma of liver"],"alternate_symbols":["LCC"],"attribute_content":[],"medgen_id":"C2239176","symbol":"HCC","name":"Hepatocellular carcinoma","keywords":["Hereditary cancer syndrome"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001402\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002899\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003007\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006750\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007256\"}","{\"db\":\"OMIM\",\"id\":\"114550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"88673\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001402\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased hepatocellular carcinoma risk\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001402\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased incidence of hepatocellular carcinoma\"}","{\"db\":\"OMIM\",\"id\":\"114550\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LIVER CELL CARCINOMA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hepatocellular+carcinoma%2C+adult/3338\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Liver cancer\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Liver+cancer/4278\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Liver cancer\"}","{\"db\":\"SNOMED CT\",\"id\":\"187769009\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Primary carcinoma of liver\"}","{\"db\":\"OMIM\",\"id\":\"114550\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCC\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001402\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25370001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"114550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"18496"}
{"type":"Disease","alternate_names":["DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT","DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC","Dilated vestibular aqueduct","Enlarged vestibular aqueduct syndrome","FOXI1-Related Pendred Syndrome","KCNJ10-Related Pendred Syndrome","Large vestibular aqueduct syndrome","NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 4","Nonsyndromic enlarged vestibular aqueduct (NSEVA)","Widened vesitbular aqueduct"],"alternate_symbols":["DVA","EVA","NSRD4","SLC26A4"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301640\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1467\",\"@Source\":\"BookShelf\"}]}]}","medgen_id":"C3538946","symbol":"DFNB4","name":"Enlarged vestibular aqueduct","keywords":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011387\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"600791\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90636\"}","{\"db\":\"OMIM\",\"id\":\"600791\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"601093.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0027\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0029\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"605646.0030\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT\"}","{\"db\":\"OMIM\",\"id\":\"601093.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"602208.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"602208.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"605646.0028\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"605646.0029\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"605646.0031\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT, DIGENIC\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011387\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dilated vestibular aqueduct\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Enlarged+Vestibular+Aqueduct+Syndrome/2542\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Enlarged vestibular aqueduct syndrome\"}","{\"db\":\"OMIM\",\"id\":\"600791\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 4\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011387\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Widened vesitbular aqueduct\"}","{\"db\":\"OMIM\",\"id\":\"600791\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DVA\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500213\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EVA\"}","{\"db\":\"OMIM\",\"id\":\"600791\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NSRD4\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011387\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1467\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600791\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"1595","public_definition":"Pendred syndrome/nonsyndromic enlarged vestibular aqueduct (PDS/NSEVA) comprises a phenotypic spectrum of sensorineural hearing loss (SNHL) that is usually congenital and often severe to profound (although mild-to-moderate progressive hearing impairment also occurs), vestibular dysfunction, and temporal bone abnormalities (bilateral enlarged vestibular aqueduct with or without cochlear hypoplasia). PDS also includes development of euthyroid goiter in late childhood to early adulthood whereas NSEVA does not."}
{"type":"Disease","alternate_names":["Deafness with goiter","Goiter-deafness syndrome","HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B","Pendred's syndrome","SLC26A4-Related Pendred Syndrome","THYROID DYSHORMONOGENESIS 2B","THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"],"alternate_symbols":["SLC26A4","TDH2B"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301640\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1467\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}}]}","medgen_id":"C0271829","symbol":"PDS","name":"Pendred syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010134\"}","{\"db\":\"OMIM\",\"id\":\"274600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"705\"}","{\"db\":\"OMIM\",\"id\":\"274600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pendred+syndrome/5656\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pendred's syndrome\"}","{\"db\":\"SNOMED CT\",\"id\":\"70348004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pendred's syndrome\"}","{\"db\":\"OMIM\",\"id\":\"274600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THYROID DYSHORMONOGENESIS 2B\"}","{\"db\":\"OMIM\",\"id\":\"274600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B\"}","{\"db\":\"OMIM\",\"id\":\"274600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TDH2B\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4271\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"pendred-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1467\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"274600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"3780","gard_id":"4271","public_definition":"Pendred syndrome/nonsyndromic enlarged vestibular aqueduct (PDS/NSEVA) comprises a phenotypic spectrum of sensorineural hearing loss (SNHL) that is usually congenital and often severe to profound (although mild-to-moderate progressive hearing impairment also occurs), vestibular dysfunction, and temporal bone abnormalities (bilateral enlarged vestibular aqueduct with or without cochlear hypoplasia). PDS also includes development of euthyroid goiter in late childhood to early adulthood whereas NSEVA does not."}
{"type":"Disease","alternate_names":["Kjer-type optic atrophy","Optic Atrophy Type 1","Optic Atrophy, Autosomal Dominant","Optic atrophy, juvenile"],"alternate_symbols":["OAK"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301426\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1248\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0338508","symbol":"OPA1","name":"Dominant hereditary optic atrophy","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"165500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98673\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1248\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Optic Atrophy Type 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Optic+atrophy+1/5380\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Optic Atrophy Type 1\"}","{\"db\":\"OMIM\",\"id\":\"165500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OAK\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dominant+hereditary+optic+atrophy/8280\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"2065009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1248\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"165500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"5679","public_definition":"Optic atrophy type 1 (OPA1, or Kjer type optic atrophy) is characterized by bilateral and symmetric optic nerve pallor associated with insidious decrease in visual acuity (usually between ages 4 and 6 years), visual field defects, and color vision defects. Visual impairment is usually moderate (6/10 to 2/10), but ranges from mild or even insignificant to severe (legal blindness with acuity \u003c1/20). The visual field defect is typically centrocecal, central, or paracentral; it is often large in those with severe disease. The color vision defect is often described as acquired blue-yellow loss (tritanopia). Other findings can include auditory neuropathy resulting in sensorineural hearing loss that ranges from severe and congenital to subclinical (i.e., identified by specific audiologic testing only). Visual evoked potentials are typically absent or delayed; pattern electroretinogram shows an abnormal N95:P50 ratio. Tritanopia is the classic feature of color vision defect, but more diffuse nonspecific dyschromatopsia is not uncommon. Ophthalmoscopic examination discloses temporal or diffuse pallor of the optic discs, sometimes associated with optic disc excavation. The neuroretinal rim shows some pallor in most cases, sometimes associated with a temporal pigmentary gray crescent."}
{"type":"Disease","alternate_names":[],"alternate_symbols":["LI1"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301593\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1420\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0020758","name":"Congenital ichthyosis of skin","keywords":[],"xrefs":["{\"db\":\"SNOMED CT\",\"id\":\"13059002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1420\",\"ref_field\":\"public_definition\"}"],"id":"9461","public_definition":"Autosomal recessive congenital ichthyosis (ARCI) encompasses several forms of nonsyndromic ichthyosis. Although most neonates with ARCI are collodion babies, the clinical presentation and severity of ARCI may vary significantly, ranging from harlequin ichthyosis, the most severe and often fatal form, to lamellar ichthyosis (LI) and (nonbullous) congenital ichthyosiform erythroderma (CIE). These phenotypes are now recognized to fall on a continuum; however, the phenotypic descriptions are clinically useful for clarification of prognosis and management. Infants with harlequin ichthyosis are usually born prematurely and are encased in thick, hard, armor-like plates of cornified skin that severely restrict movement. Life-threatening complications in the immediate postnatal period include respiratory distress, feeding problems, and systemic infection. Collodion babies are born with a taut, shiny, translucent or opaque membrane that encases the entire body and lasts for days to weeks. LI and CIE are seemingly distinct phenotypes: classic, severe LI with dark brown, plate-like scale with no erythroderma and CIE with finer whiter scale and underlying generalized redness of the skin. Affected individuals with severe involvement can have ectropion, eclabium, scarring alopecia involving the scalp and eyebrows, and palmar and plantar keratoderma. Besides these major forms of nonsyndromic ichthyosis, a few rare subtypes have been recognized, such as bathing suit ichthyosis, self-improving collodion ichthyosis, or ichthyosis-prematurity syndrome."}
{"type":"Disease","alternate_names":["Osteopetrosis infantile malignant 2","infantile malignant CLCN7-related recessive osteopetrosis"],"alternate_symbols":["OPTB4"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301306\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1127\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1969106","name":"Autosomal recessive osteopetrosis 4","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012676\"}","{\"db\":\"OMIM\",\"id\":\"611490\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"667\"}","{\"db\":\"OMIM\",\"id\":\"611490\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OPTB4\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5993\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012676\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1127\",\"ref_field\":\"public_definition\"}"],"id":"5705","gard_id":"5993","public_definition":"The spectrum of CLCN7-related osteopetrosis includes infantile malignant CLCN7-related recessive osteopetrosis (ARO), intermediate autosomal osteopetrosis (IAO), and autosomal dominant osteopetrosis type II (ADOII, Albers-Schönberg disease). Onset of ARO is in infancy. Findings may include: fractures; poor growth; sclerosis of the skull base (with or without choanal stenosis or hydrocephalus) resulting in optic nerve compression, facial palsy, and hearing loss; absence of the bone marrow cavity resulting in severe anemia and thrombocytopenia; dental abnormalities, odontomas, and risk for mandibular osteomyelitis; and hypocalcemia with tetanic seizures and secondary hyperparathyroidism. Without treatment maximal life span in ARO is ten years. Onset of IAO is in childhood. Findings may include fractures after minor trauma, characteristic skeletal radiographic changes found incidentally, mild anemia, and occasional visual impairment secondary to optic nerve compression. Life expectancy in IAO is usually normal. Onset of ADOII is usually late childhood or adolescence. Findings may include: fractures (in any long bone and/or the posterior arch of a vertebra), scoliosis, hip osteoarthritis, and osteomyelitis of the mandible or septic osteitis or osteoarthritis elsewhere. Cranial nerve compression is rare."}
{"type":"Disease","alternate_names":["Hyper IgM immunodeficiency, X-linked","Hyper IgM syndrome 1","Hyper-IgM Immunodeficiency Syndrome, Type 1","IMMUNODEFICIENCY 3","Immunodeficiency with hyper IgM type 1"],"alternate_symbols":["HIGM","HIGM1","IHIS","IMD3","XHIM"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301576\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1402\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0398689","name":"X-linked hyper-IgM syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010626\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101088\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Immunodeficiency+with+hyper+IgM+type+1/3776\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Immunodeficiency with hyper IgM type 1\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HIGM\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HIGM1\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IHIS\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IMD3\"}","{\"db\":\"OMIM\",\"id\":\"308230\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XHIM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"73\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010626\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1402\",\"ref_field\":\"public_definition\"}"],"id":"5326","gard_id":"73","public_definition":"X-linked hyper IgM syndrome (HIGM1), a disorder of abnormal T- and B-cell function, is characterized by low serum concentrations of IgG, IgA, and IgE with normal or elevated serum concentrations of IgM. Mitogen proliferation may be normal, but NK- and T-cell cytotoxicity can be impaired. Antigen-specific responses are usually decreased or absent. Total numbers of B cells are normal but there is a marked reduction of class-switched memory B cells. Defective oxidative burst of both neutrophils and macrophages has been reported. The range of clinical findings varies, even within the same family. More than 50% of males with HIGM1 develop symptoms by age one year, and more than 90% are symptomatic by age four years. HIGM1 usually presents in infancy with recurrent upper- and lower-respiratory tract bacterial infections, opportunistic infections including Pneumocystis jirovecii pneumonia, and recurrent or protracted diarrhea that can be infectious or noninfectious and is associated with failure to thrive. Neutropenia is common; thrombocytopenia and anemia are less commonly seen. Autoimmune and/or inflammatory disorders (such as sclerosing cholangitis) as well as increased risk for neoplasms have been reported as medical complications of this disorder. Significant neurologic complications, often the result of a CNS infection, are seen in 5%-15% of affected males. Liver disease, a serious complication of HIGM1 once observed in more than 80% of affected males by age 20 years, may be decreasing with adequate screening and treatment of Cryptosporidium infection."}
{"type":"Disease","alternate_names":["FJHN atypical","Glomerulocystic kidney disease, hypoplastic type","Hyperuricemic nephropathy, familial juvenile, atypical","MODY type 5","Maturity-onset diabetes of the young, type 5"],"alternate_symbols":["MODY5"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27929632\",\"@Source\":\"PubMed\"},{\"$\":\"NBK401562\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}]}","medgen_id":"C0431693","symbol":"RCAD","name":"Familial hypoplastic, glomerulocystic kidney","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"137920\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93111\"}","{\"db\":\"OMIM\",\"id\":\"137920\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MODY5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Maturity-onset+diabetes+of+the+young%2C+type+5/4510\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"253864004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK401562\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"137920\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4321","public_definition":"The 17q12 recurrent deletion syndrome is characterized by variable combinations of the three following findings: structural or functional abnormalities of the kidney and urinary tract, maturity-onset diabetes of the young type 5 (MODY5), and neurodevelopmental or neuropsychiatric disorders (e.g., developmental delay, intellectual disability, autism spectrum disorder, schizophrenia, anxiety, and bipolar disorder). Using a method of data analysis that avoids ascertainment bias, the authors determined that multicystic kidneys and other structural and functional kidney anomalies occur in 85% to 90% of affected individuals, MODY5 in approximately 40%, and some degree of developmental delay or learning disability in approximately 50%. MODY5 is most often diagnosed before age 25 years (range: age 10-50 years)."}
{"type":"Disease","alternate_names":["Arthro-Onychodysplasia","Fong disease","NPS 1","Onychoosteodysplasia","Osteo-Onychodysplasia","Turner-Kieser syndrome"],"alternate_symbols":["NPS1"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301311\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1132\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0027341","symbol":"NPS","name":"Nail-patella syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008061\"}","{\"db\":\"OMIM\",\"id\":\"161200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2614\"}","{\"db\":\"OMIM\",\"id\":\"161200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NPS1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7160\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nail+patella+syndrome/5098\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"22199006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1132\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"161200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"3433","gard_id":"7160","public_definition":"Nail-patella syndrome (NPS) (previously referred to as Fong's disease), encompasses the classic clinical tetrad of changes in the nails, knees, and elbows, and the presence of iliac horns. Nail changes are the most constant feature of NPS. Nails may be absent, hypoplastic, or dystrophic; ridged longitudinally or horizontally; pitted; discolored; separated into two halves by a longitudinal cleft or ridge of skin; and thin or (less often) thickened. The patellae may be small, irregularly shaped, or absent. Elbow abnormalities may include limitation of extension, pronation, and supination; cubitus valgus; and antecubital pterygia. Iliac horns are bilateral, conical, bony processes that project posteriorly and laterally from the central part of the iliac bones of the pelvis. Renal involvement, first manifest as proteinuria with or without hematuria, occurs in 30%-50% of affected individuals; end-stage renal disease occurs up to 15% of affected individuals. Primary open-angle glaucoma and ocular hypertension occur at increased frequency and at a younger age than in the general population."}
{"type":"Disease","alternate_names":["ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11","Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy11","Arrhythmogenic right ventricular dysplasia, type 11"],"alternate_symbols":["ARVC11"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301310\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1131\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C1864850","symbol":"ARVD11","name":"Arrhythmogenic right ventricular cardiomyopathy, type 11","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012506\"}","{\"db\":\"OMIM\",\"id\":\"610476\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"125645.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11\"}","{\"db\":\"OMIM\",\"id\":\"125645.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11\"}","{\"db\":\"OMIM\",\"id\":\"610476\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11\"}","{\"db\":\"OMIM\",\"id\":\"610476\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ARVC11\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Arrhythmogenic+right+ventricular+cardiomyopathy%2C+type+11/7707\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1131\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610476\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"434","public_definition":"Arrhythmogenic right ventricular cardiomyopathy (ARVC) – previously referred to as arrhythmogenic right ventricular dysplasia (ARVD) – is characterized by progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia and sudden death in young individuals and athletes. It primarily affects the right ventricle, and it may also involve the left ventricle. The presentation of disease is highly variable even within families, and some affected individuals may not meet established clinical criteria. The mean age at diagnosis is 31 years (±13; range: 4-64 years)."}
{"type":"Disease","alternate_names":["ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8","Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy 8","Arrhythmogenic right ventricular cardiomyopathy, type 8"],"alternate_symbols":["ARVC8"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301310\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1131\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C1843896","symbol":"ARVD8","name":"Arrhythmogenic right ventricular dysplasia 8","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011831\"}","{\"db\":\"OMIM\",\"id\":\"607450\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"125647.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8\"}","{\"db\":\"OMIM\",\"id\":\"125647.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8\"}","{\"db\":\"OMIM\",\"id\":\"125647.0024\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8\"}","{\"db\":\"OMIM\",\"id\":\"607450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Arrhythmogenic+right+ventricular+cardiomyopathy%2C+type+8/7711\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Arrhythmogenic right ventricular cardiomyopathy, type 8\"}","{\"db\":\"OMIM\",\"id\":\"607450\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ARVC8\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011831\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1131\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607450\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4615","public_definition":"Arrhythmogenic right ventricular cardiomyopathy (ARVC) – previously referred to as arrhythmogenic right ventricular dysplasia (ARVD) – is characterized by progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia and sudden death in young individuals and athletes. It primarily affects the right ventricle, and it may also involve the left ventricle. The presentation of disease is highly variable even within families, and some affected individuals may not meet established clinical criteria. The mean age at diagnosis is 31 years (±13; range: 4-64 years)."}
{"type":"Disease","alternate_names":["ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9","Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy 9","Arrhythmogenic right ventricular cardiomyopathy, type 9"],"alternate_symbols":["ARVC9"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301310\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1131\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C1836906","symbol":"ARVD9","name":"Arrhythmogenic right ventricular dysplasia 9","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012180\"}","{\"db\":\"OMIM\",\"id\":\"609040\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"602861.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9\"}","{\"db\":\"OMIM\",\"id\":\"602861.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9\"}","{\"db\":\"OMIM\",\"id\":\"602861.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9\"}","{\"db\":\"OMIM\",\"id\":\"602861.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9\"}","{\"db\":\"OMIM\",\"id\":\"609040\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Arrhythmogenic+right+ventricular+cardiomyopathy%2C+type+9/7712\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Arrhythmogenic right ventricular cardiomyopathy, type 9\"}","{\"db\":\"OMIM\",\"id\":\"609040\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ARVC9\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012180\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1131\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609040\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4616","public_definition":"Arrhythmogenic right ventricular cardiomyopathy (ARVC) – previously referred to as arrhythmogenic right ventricular dysplasia (ARVD) – is characterized by progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia and sudden death in young individuals and athletes. It primarily affects the right ventricle, and it may also involve the left ventricle. The presentation of disease is highly variable even within families, and some affected individuals may not meet established clinical criteria. The mean age at diagnosis is 31 years (±13; range: 4-64 years)."}
{"type":"Disease","alternate_names":["Autosomal dominant hidrotic ectodermal dysplasia","CLOUSTON HIDROTIC ECTODERMAL DYSPLASIA","Clouston syndrome","Clouston's hidrotic ectodermal dysplasia","ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE","Ectodermal dysplasia 2, hidrotic","Hidrotic ectodermal dysplasia"],"alternate_symbols":["ECTD2","ED2","HED","HED2"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301379\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1200\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0162361","symbol":"GJB6","name":"Hidrotic ectodermal dysplasia syndrome","keywords":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007529\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007510\"}","{\"db\":\"OMIM\",\"id\":\"129500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"189\"}","{\"db\":\"OMIM\",\"id\":\"129500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CLOUSTON HIDROTIC ECTODERMAL DYSPLASIA\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007510\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Clouston syndrome\"}","{\"db\":\"OMIM\",\"id\":\"129500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE\"}","{\"db\":\"OMIM\",\"id\":\"604418.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007529\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hidrotic ectodermal dysplasia\"}","{\"db\":\"OMIM\",\"id\":\"129500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ECTD2\"}","{\"db\":\"OMIM\",\"id\":\"129500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HED2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hidrotic+ectodermal+dysplasia+syndrome/8550\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"54209007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1200\",\"ref_field\":\"public_definition\"}"],"id":"4993","public_definition":"Hidrotic ectodermal dysplasia 2, or Clouston syndrome (referred to as HED2 throughout this GeneReview) is characterized by a triad of major clinical features including partial-to-complete alopecia, nail dystrophy, and palmoplantar hyperkeratosis. Sweating is preserved and there are usually no dental anomalies. Sparse scalp hair and dysplastic nails are seen early in life. In infancy, scalp hair is fine, sparse, and brittle. Progressive hair loss may lead to total alopecia by puberty. The nails may be milky white in early childhood; they gradually become dystrophic, thick, and distally separated from the nail bed. Palmoplantar keratoderma may develop during childhood and increases in severity with age. Associated features may include cutaneous hyperpigmentation (particularly over the joints) and finger clubbing. The clinical manifestations are highly variable even within the same family."}
{"type":"Disease","alternate_names":["Cystine diathesis","Cystine disease","Cystine storage disease","Cystinoses","Cystinosin, defect of","Lysosomal cystine transport protein, defect of"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301574\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1400\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C2931187","symbol":"CTNS","name":"Nephropathic cystinosis","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"219800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"213\"}","{\"db\":\"Orphanet\",\"id\":\"411629\"}","{\"db\":\"GeneTests\",\"id\":\"54105\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephropathic+cystinosis/5143\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1400\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529128\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"219800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"15909","public_definition":"Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation."}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7","KCNQ2-Related Neonatal Epileptic Encephalopathy"],"alternate_symbols":["EIEE7"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20437616\",\"@Source\":\"PubMed\"},{\"$\":\"NBK32534\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C3150986","symbol":"DEE7","name":"Early infantile epileptic encephalopathy 7","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013387\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"439218\"}","{\"db\":\"OMIM\",\"id\":\"602235.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"602235.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"602235.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"602235.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"602235.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"602235.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"602235.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 7\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE7\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13060\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+7/8345\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK32534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"15768","gard_id":"13060","public_definition":"KCNQ2-related disorders represent a continuum of overlapping neonatal epileptic phenotypes caused by a heterozygous pathogenic variant in KCNQ2. The clinical features of KCNQ2-related disorders range from KCNQ2-related benign familial neonatal epilepsy (KCNQ2-BFNE) at the mild end to KCNQ2-related neonatal epileptic encephalopathy (KCNQ2-NEE) at the severe end. KCNQ2-BFNE is characterized by a wide spectrum of seizure types (tonic or apneic episodes, focal clonic activity, or autonomic changes) that start in otherwise healthy infants between the second and eighth day of life and spontaneously disappear between the first and the sixth to 12th month of life. Motor activity may be confined to one body part, migrate to other body regions, or generalize. Seizures are generally brief, lasting one to two minutes. Rarely, KCNQ2-BFNE may evolve into status epilepticus. About 10%-15% of individuals with BFNE develop epileptic seizures later in life. KCNQ2-NEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features. Seizures generally cease between ages nine months and four years. At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia and thalamic hyperintensities that later resolve. Moderate to severe developmental impairment is present."}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY, 6","Dravet syndrome","EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6","Epilepsy, Myoclonic, Infantile, Severe","Epileptic encephalopathy, early infantile, 6 (Dravet syndrome)","SCN1A-Related Intractable Childhood Epilepsy with Generalized Tonic-Clonic Seizures","SCN1A-Related Severe Myoclonic Epilepsy in Infancy"],"alternate_symbols":["DEE6","EIEE6","ICE-GTC","SME","SMEI"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301494\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1318\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20298421\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Orphanet, 2008\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Dravet syndrome, 2008\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_Dravet.pdf\"}}]}","medgen_id":"C4551549","symbol":"DRVT","name":"Severe myoclonic epilepsy in infancy","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"33069\"}","{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY, 6\"}","{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6\"}","{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DEE6\"}","{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE6\"}","{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SMEI\"}","{\"db\":\"GeneTests\",\"id\":\"219513\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dravet+Syndrome/2332\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"230437002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1318\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607208\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4140","public_definition":"SCN1A seizure disorders encompass a spectrum that ranges from simple febrile seizures and generalized epilepsy with febrile seizures plus (GEFS+) at the mild end to Dravet syndrome and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC) at the severe end. Phenotypes with intractable seizures including Dravet syndrome are often associated with cognitive decline. Less commonly observed phenotypes include myoclonic astatic epilepsy (MAE), Lennox-Gastaut syndrome, infantile spasms, epilepsy with focal seizures, and vaccine-related encephalopathy and seizures. The phenotype of SCN1A seizure disorders can vary even within the same family."}
{"type":"Disease","alternate_names":["Anus, imperforate, with hand, foot and ear anomalies","DEAFNESS, SENSORINEURAL, WITH IMPERFORATE ANUS AND THUMB ANOMALIES","Deafness, sensorineural, with imperforate anus and hypoplastic thumbs","Renal-ear-anal-radial syndrome"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301618\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1445\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4551481","symbol":"TBS1","name":"Townes-Brocks syndrome 1","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0054581\"}","{\"db\":\"OMIM\",\"id\":\"107480\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"857\"}","{\"db\":\"OMIM\",\"id\":\"107480\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEAFNESS, SENSORINEURAL, WITH IMPERFORATE ANUS AND THUMB ANOMALIES\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1445\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"107480\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"6067","public_definition":"Townes-Brocks syndrome (TBS) is characterized by the triad of imperforate anus (84%), dysplastic ears (87%; overfolded superior helices and preauricular tags; frequently associated with sensorineural and/or conductive hearing impairment [65%]), and thumb malformations (89%; triphalangeal thumbs, duplication of the thumb [preaxial polydactyly], and rarely hypoplasia of the thumbs). Renal impairment (42%), including end-stage renal disease (ESRD), may occur with or without structural abnormalities (mild malrotation, ectopia, horseshoe kidney, renal hypoplasia, polycystic kidneys, vesicoutereral reflux). Congenital heart disease occurs in 25%. Foot malformations (52%; flat feet, overlapping toes) and genitourinary malformations (36%) are common. Intellectual disability occurs in approximately 10% of individuals. Rare features include iris coloboma, Duane anomaly, Arnold-Chiari malformation type 1, and growth retardation."}
{"type":"Disease","alternate_names":["Anesthesia related hyperthermia","Fulminating hyperpyrexia","Malignant hyperpyrexia","Malignant hyperthermia suceptibility 1","Pharmacogenic myopathy"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301325\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1146\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3110041\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Sei et al., 2004\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"14870754\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"EMHG, 2018\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"European Malignant Hyperthermia Group Guidelines, Causative mutations\"},\"URL\":{\"$\":\"https://www.emhg.org/diagnostic-mutations\"}},{\"@Abbrev\":\"Orphanet, 2013\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet Emergency Guidelines: Malignant hyperthermia\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_MalignantHyperthermia-enPro649.pdf\"}}]}","medgen_id":"C2930980","symbol":"MHS1","name":"Malignant hyperthermia, susceptibility to, 1","keywords":["Pharmacogenetic"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007783\"}","{\"db\":\"OMIM\",\"id\":\"145600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"423\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3363\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1146\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"145600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"2639","gard_id":"3363","public_definition":"Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism. Manifestations of malignant hyperthermia (MH) are precipitated by certain volatile anesthetics (i.e., halothane, isoflurane, sevoflurane, desflurane, enflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine). The triggering substances cause uncontrolled release of calcium from the sarcoplasmic reticulum and may promote entry of extracellular calcium into the myoplasm, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate. Affected individuals experience acidosis, hypercapnia, tachycardia, hyperthermia, muscle rigidity, compartment syndrome, rhabdomyolysis with subsequent increase in serum creatine kinase (CK) concentration, hyperkalemia with a risk for cardiac arrhythmia or even cardiac arrest, and myoglobinuria with a risk for renal failure. In nearly all cases, the first manifestations of MH (tachycardia and tachypnea) occur in the operating room; however, MH may also occur in the early postoperative period. There is mounting evidence that some individuals with MHS will also develop MH with exercise and/or on exposure to hot environments. Without proper and prompt treatment with dantrolene sodium, mortality is extremely high."}
{"type":"Disease","alternate_names":["MACROCEPHALY-CAPILLARY MALFORMATION","MEGALENCEPHALY-CAPILLARY MALFORMATION SYNDROME","MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC","Macrocephaly cutis marmorata telangiectatica congenita","Macrocephaly-capillary malformation syndrome (M-CM, MCAP)","Megalencephaly cutis marmorata telangiectatica congenita","Megalencephaly-Capillary Malformation (MCAP) Syndrome","Megalocephaly cutis marmorata telangiectatica congenita"],"alternate_symbols":["M-CMTC","MCM"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23946963\",\"@Source\":\"PubMed\"},{\"$\":\"NBK153722\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1865285","symbol":"MCAP","name":"Megalencephaly-capillary malformation-polymicrogyria syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011240\"}","{\"db\":\"OMIM\",\"id\":\"602501\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"60040\"}","{\"db\":\"OMIM\",\"id\":\"602501\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACROCEPHALY-CAPILLARY MALFORMATION\"}","{\"db\":\"OMIM\",\"id\":\"602501\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALENCEPHALY-CAPILLARY MALFORMATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"171834.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME, SOMATIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Macrocephaly-Capillary+Malformation/4560\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Megalencephaly cutis marmorata telangiectatica congenita\"}","{\"db\":\"OMIM\",\"id\":\"602501\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6950\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011240\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK153722\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602501\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"2584","gard_id":"6950","public_definition":"PIK3CA-associated segmental overgrowth includes disorders of brain (e.g., MCAP [megalencephaly-capillary malformation] syndrome, hemimegalencephaly); and segmental body overgrowth (e.g., CLOVES [congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies] syndrome, fibroadipose hyperplasia [FH]). Heterozygous (usually somatic mosaic) pathogenic variants of PIK3CA are causative. MCAP syndrome is characterized by the major findings of (1) megalencephaly (MEG) or hemimegalencephaly (HMEG) associated with neurologic findings of hypotonia, seizures, and mild to severe intellectual disability; and (2) cutaneous capillary malformations with focal or generalized somatic overgrowth. Additional findings can include digital anomalies (syndactyly, polydactyly), cortical malformations – most distinctively polymicrogyria (PMG); and variable connective tissue dysplasia. CLOVES (or CLOVE) syndrome and fibroadipose hyperplasia (FH) may be associated with (1) MEG or HMEG; and (2) patchy segmental overgrowth associated with skeletal anomalies, lipomatosis, vascular malformations, and epidermal nevi."}
{"type":"Disease","alternate_names":["Connexin 26 deafness","DFNB 1 Nonsyndromic Hearing Loss and Deafness","Deafness nonsyndromic, Connexin 26 linked","GJB2-Related DFNB 1 Nonsyndromic Hearing Loss and Deafness","GJB2-related deafness","GJB6-Related DFNB 1 Nonsyndromic Hearing Loss and Deafness"],"alternate_symbols":["DFNB1"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301449\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1272\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NICE, 2009\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"National Institute for Health and Clinical Excellence, Cochlear implants for children and adults with severe to profound deafness, 2009\"},\"URL\":{\"$\":\"https://www.guideline.gov/content.aspx?id=14232\"}}]}","medgen_id":"C2673759","symbol":"DFNB1A","name":"Deafness, autosomal recessive 1A","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009076\"}","{\"db\":\"OMIM\",\"id\":\"220290\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90636\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1697\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+autosomal+recessive+1A/8159\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1272\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"220290\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"946","gard_id":"1697","public_definition":"Nonsyndromic hearing loss and deafness (DFNB1) is characterized by congenital non-progressive mild-to-profound sensorineural hearing impairment. No other associated medical findings are present."}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4","STXBP1-Related Epileptic Encephalopathy"],"alternate_symbols":["EIEE4"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27905812\",\"@Source\":\"PubMed\"},{\"$\":\"NBK396561\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C2677326","symbol":"DEE4","name":"Early infantile epileptic encephalopathy 4","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012812\"}","{\"db\":\"OMIM\",\"id\":\"612164\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1934\"}","{\"db\":\"Orphanet\",\"id\":\"33069\"}","{\"db\":\"OMIM\",\"id\":\"602926.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"602926.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"602926.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"602926.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"602926.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"602926.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"602926.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"612164\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 4\"}","{\"db\":\"OMIM\",\"id\":\"612164\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE4\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12900\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+4/8343\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK396561\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612164\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"1178","gard_id":"12900","public_definition":"STXBP1 encephalopathy with epilepsy is characterized by early-onset encephalopathy with epilepsy (i.e., moderate to severe intellectual disability, refractory seizures, and ongoing epileptiform activity). The median age of onset of seizures is six weeks (range 1 day to 13 years). Seizure types can include infantile spasms; generalized tonic-clonic, clonic, or tonic seizures; and myoclonic, focal, atonic, and absence seizures. Epilepsy syndromes can include Ohtahara syndrome, West syndrome, Lennox-Gaustaut syndrome, and Dravet syndrome (not SCN1A-related), classic Rett syndrome (not MECP2-related), and atypical Rett syndrome (not CDKL5-related). The EEG is characterized by focal epileptic activity, burst suppression, hypsarrhythmia, or generalized spike-and-slow waves. Other findings can include abnormal tone, movement disorders (especially ataxia and dystonia), and behavior disorders (including autism spectrum disorder). Feeding difficulties are common."}
{"type":"Disease","alternate_names":["Brachmann de Lange syndrome","Typus degenerativus amstelodamensis"],"alternate_symbols":["BDLS"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301283\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1104\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4551851","symbol":"CDLS1","name":"Cornelia de Lange syndrome 1","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007387\"}","{\"db\":\"OMIM\",\"id\":\"122470\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199\"}","{\"db\":\"OMIM\",\"id\":\"122470\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BDLS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cornelia+de+Lange+Syndrome+1/1918\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1104\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"122470\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"1016","public_definition":"Cornelia de Lange syndrome (CdLS) encompasses a spectrum of findings from mild to severe. Severe (classic) CdLS is characterized by distinctive facial features, growth restriction (prenatal onset; \u003c5th centile throughout life), hypertrichosis, and upper-limb reduction defects that range from subtle phalangeal abnormalities to oligodactyly (missing digits). Craniofacial features include synophrys, highly arched and/or thick eyebrows, long eyelashes, short nasal bridge with anteverted nares, small widely spaced teeth, and microcephaly. Individuals with a milder phenotype have less severe growth, cognitive, and limb involvement, but often have facial features consistent with CdLS. Across the CdLS spectrum IQ ranges from below 30 to 102 (mean: 53). Many individuals demonstrate autistic and self-destructive tendencies. Other frequent findings include cardiac septal defects, gastrointestinal dysfunction, hearing loss, myopia, and cryptorchidism or hypoplastic genitalia."}
{"type":"Disease","alternate_names":["Cornelia de Lange syndrome 2"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301283\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1104\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1802395","symbol":"CDLS2","name":"Congenital muscular hypertrophy-cerebral syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010370\"}","{\"db\":\"OMIM\",\"id\":\"300590\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010370\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cornelia de Lange syndrome 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+hypertrophy-cerebral+syndrome/8077\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"55016009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1104\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300590\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4850","public_definition":"Cornelia de Lange syndrome (CdLS) encompasses a spectrum of findings from mild to severe. Severe (classic) CdLS is characterized by distinctive facial features, growth restriction (prenatal onset; \u003c5th centile throughout life), hypertrichosis, and upper-limb reduction defects that range from subtle phalangeal abnormalities to oligodactyly (missing digits). Craniofacial features include synophrys, highly arched and/or thick eyebrows, long eyelashes, short nasal bridge with anteverted nares, small widely spaced teeth, and microcephaly. Individuals with a milder phenotype have less severe growth, cognitive, and limb involvement, but often have facial features consistent with CdLS. Across the CdLS spectrum IQ ranges from below 30 to 102 (mean: 53). Many individuals demonstrate autistic and self-destructive tendencies. Other frequent findings include cardiac septal defects, gastrointestinal dysfunction, hearing loss, myopia, and cryptorchidism or hypoplastic genitalia."}
{"type":"Disease","alternate_names":["CORNELIA DE LANGE SYNDROME 3 WITH OR WITHOUT MIDLINE BRAIN DEFECTS"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301283\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1104\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1853099","symbol":"CDLS3","name":"Cornelia de Lange syndrome 3","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012555\"}","{\"db\":\"OMIM\",\"id\":\"610759\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199\"}","{\"db\":\"OMIM\",\"id\":\"610759\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORNELIA DE LANGE SYNDROME 3 WITH OR WITHOUT MIDLINE BRAIN DEFECTS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cornelia+de+Lange+Syndrome+3/1920\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1104\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610759\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"846","public_definition":"Cornelia de Lange syndrome (CdLS) encompasses a spectrum of findings from mild to severe. Severe (classic) CdLS is characterized by distinctive facial features, growth restriction (prenatal onset; \u003c5th centile throughout life), hypertrichosis, and upper-limb reduction defects that range from subtle phalangeal abnormalities to oligodactyly (missing digits). Craniofacial features include synophrys, highly arched and/or thick eyebrows, long eyelashes, short nasal bridge with anteverted nares, small widely spaced teeth, and microcephaly. Individuals with a milder phenotype have less severe growth, cognitive, and limb involvement, but often have facial features consistent with CdLS. Across the CdLS spectrum IQ ranges from below 30 to 102 (mean: 53). Many individuals demonstrate autistic and self-destructive tendencies. Other frequent findings include cardiac septal defects, gastrointestinal dysfunction, hearing loss, myopia, and cryptorchidism or hypoplastic genitalia."}
{"type":"Disease","alternate_names":["CORNELIA DE LANGE SYNDROME 4 WITH OR WITHOUT MIDLINE BRAIN DEFECTS"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301283\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1104\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C3553517","symbol":"CDLS4","name":"Cornelia de Lange syndrome 4","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013864\"}","{\"db\":\"OMIM\",\"id\":\"614701\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199\"}","{\"db\":\"OMIM\",\"id\":\"614701\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORNELIA DE LANGE SYNDROME 4 WITH OR WITHOUT MIDLINE BRAIN DEFECTS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1104\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614701\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"17306","public_definition":"Cornelia de Lange syndrome (CdLS) encompasses a spectrum of findings from mild to severe. Severe (classic) CdLS is characterized by distinctive facial features, growth restriction (prenatal onset; \u003c5th centile throughout life), hypertrichosis, and upper-limb reduction defects that range from subtle phalangeal abnormalities to oligodactyly (missing digits). Craniofacial features include synophrys, highly arched and/or thick eyebrows, long eyelashes, short nasal bridge with anteverted nares, small widely spaced teeth, and microcephaly. Individuals with a milder phenotype have less severe growth, cognitive, and limb involvement, but often have facial features consistent with CdLS. Across the CdLS spectrum IQ ranges from below 30 to 102 (mean: 53). Many individuals demonstrate autistic and self-destructive tendencies. Other frequent findings include cardiac septal defects, gastrointestinal dysfunction, hearing loss, myopia, and cryptorchidism or hypoplastic genitalia."}
{"type":"Disease","alternate_names":["Acro-dermato-ungual-lacrimal-tooth syndrome"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20556892\",\"@Source\":\"PubMed\"},{\"$\":\"NBK43797\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1863204","name":"ADULT syndrome","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007072\"}","{\"db\":\"OMIM\",\"id\":\"103285\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"978\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"384\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"ADULT+Syndrome/252\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK43797\",\"ref_field\":\"public_definition\"}"],"id":"36","gard_id":"384","public_definition":"The TP63-related disorders comprise six overlapping phenotypes: Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome (which includes Rapp-Hodgkin syndrome). Acro-dermo-ungual-lacrimal-tooth (ADULT) syndrome. Ectrodactyly, ectodermal dysplasia, cleft lip/palate syndrome 3 (EEC3). Limb-mammary syndrome. Split-hand/foot malformation type 4 (SHFM4). Isolated cleft lip/cleft palate (orofacial cleft 8). Individuals typically have varying combinations of ectodermal dysplasia (subjective hypohidrosis, nail dysplasia, sparse hair, tooth abnormalities), cleft lip/palate, split-hand/foot malformation/syndactyly, lacrimal duct obstruction, hypopigmentation, and hypoplastic breasts and/or nipples. Findings associated with a single phenotype include ankyloblepharon filiforme adnatum (tissue strands that completely or partially fuse the upper and lower eyelids), skin erosions especially on the scalp associated with areas of scarring and alopecia, hypospadias, trismus, and excessive freckling."}
{"type":"Disease","alternate_names":[],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301347\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1168\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4225374","symbol":"CMS2A","name":"Myasthenic syndrome, congenital, 2a, slow-channel","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014581\"}","{\"db\":\"OMIM\",\"id\":\"616313\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"590\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1168\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616313\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"33150","public_definition":"Congenital myasthenic syndromes (designated as CMS throughout this entry) are characterized by fatigable weakness of skeletal muscle (e.g., ocular, bulbar, limb muscles) with onset at or shortly after birth or in early childhood; rarely, symptoms may not manifest until later in childhood. Cardiac and smooth muscle are usually not involved. Severity and course of disease are highly variable, ranging from minor symptoms to progressive disabling weakness. In some subtypes of CMS, myasthenic symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency may be precipitated by fever, infections, or excitement. Major findings of the neonatal-onset subtype include: respiratory insufficiency with sudden apnea and cyanosis; feeding difficulties; poor suck and cry; choking spells; eyelid ptosis; and facial, bulbar, and generalized weakness. Arthrogryposis multiplex congenita may also be present. Stridor in infancy may be an important clue to CMS. Later childhood-onset subtypes show abnormal muscle fatigability with difficulty in activities such as running or climbing stairs; motor milestones may be delayed; fluctuating eyelid ptosis and fixed or fluctuating extraocular muscle weakness are common presentations."}
{"type":"Disease","alternate_names":["Myasthenic syndrome, congenital, 3B, fast-channel"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301347\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1168\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4225371","symbol":"CMS3B","name":"Congenital myasthenic syndrome 3B","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014584\"}","{\"db\":\"OMIM\",\"id\":\"616322\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"590\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0014584\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1168\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616322\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"33153","public_definition":"Congenital myasthenic syndromes (designated as CMS throughout this entry) are characterized by fatigable weakness of skeletal muscle (e.g., ocular, bulbar, limb muscles) with onset at or shortly after birth or in early childhood; rarely, symptoms may not manifest until later in childhood. Cardiac and smooth muscle are usually not involved. Severity and course of disease are highly variable, ranging from minor symptoms to progressive disabling weakness. In some subtypes of CMS, myasthenic symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency may be precipitated by fever, infections, or excitement. Major findings of the neonatal-onset subtype include: respiratory insufficiency with sudden apnea and cyanosis; feeding difficulties; poor suck and cry; choking spells; eyelid ptosis; and facial, bulbar, and generalized weakness. Arthrogryposis multiplex congenita may also be present. Stridor in infancy may be an important clue to CMS. Later childhood-onset subtypes show abnormal muscle fatigability with difficulty in activities such as running or climbing stairs; motor milestones may be delayed; fluctuating eyelid ptosis and fixed or fluctuating extraocular muscle weakness are common presentations."}
{"type":"Disease","alternate_names":["Myasthenic Syndromes, Congenital, Slow Channel","Myasthenic syndrome, congenital, postsynaptic slow-channel","Slow-Channel Congenital Myasthenia Syndrome"],"alternate_symbols":["SCCMS"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301347\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1168\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0751885","name":"Myasthenic syndrome, slow-channel congenital","keywords":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"590\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myasthenic+syndrome%2C+congenital%2C+slow-channel/5001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1168\",\"ref_field\":\"public_definition\"}"],"id":"5578","public_definition":"Congenital myasthenic syndromes (designated as CMS throughout this entry) are characterized by fatigable weakness of skeletal muscle (e.g., ocular, bulbar, limb muscles) with onset at or shortly after birth or in early childhood; rarely, symptoms may not manifest until later in childhood. Cardiac and smooth muscle are usually not involved. Severity and course of disease are highly variable, ranging from minor symptoms to progressive disabling weakness. In some subtypes of CMS, myasthenic symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency may be precipitated by fever, infections, or excitement. Major findings of the neonatal-onset subtype include: respiratory insufficiency with sudden apnea and cyanosis; feeding difficulties; poor suck and cry; choking spells; eyelid ptosis; and facial, bulbar, and generalized weakness. Arthrogryposis multiplex congenita may also be present. Stridor in infancy may be an important clue to CMS. Later childhood-onset subtypes show abnormal muscle fatigability with difficulty in activities such as running or climbing stairs; motor milestones may be delayed; fluctuating eyelid ptosis and fixed or fluctuating extraocular muscle weakness are common presentations."}
{"type":"Disease","alternate_names":["Dense deposit disease","MPGN 2","Membranoproliferative glomerulonephritis type 2","Membranoproliferative glomerulonephritis type II","Mesangiocapillary glomerulonephritis type 2"],"alternate_symbols":["DDD"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301598\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1425\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0268743","name":"Mesangiocapillary glomerulonephritis, type II","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0019736\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004746\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dense deposit disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004746\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Membranoproliferative glomerulonephritis type II\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500217\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503164\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521872\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"SNOMED CT\",\"id\":\"59479006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1425\",\"ref_field\":\"public_definition\"}"],"disease_mechanism_id":"283","id":"14741","disease_mechanism":"Other","public_definition":"C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface) that is rarely inherited in a simple mendelian fashion. C3G affects individuals of all ages, with a median age at diagnosis of 23 years. Individuals with C3G typically present with hematuria, proteinuria, hematuria and proteinuria, acute nephritic syndrome or nephrotic syndrome, and low levels of the complement component C3. Spontaneous remission of C3G is uncommon, and about half of affected individuals develop end-stage renal disease (ESRD) within ten years of diagnosis, occasionally developing the late comorbidity of impaired visual acuity."}
{"type":"Disease","alternate_names":["CLOVE SYNDROME","CLOVES","CLOVES SYNDROME","CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI, SOMATIC","CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, EPIDERMAL NEVI, AND SKELETAL/SPINAL ABNORMALITIES"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23946963\",\"@Source\":\"PubMed\"},{\"$\":\"NBK153722\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C2752042","name":"Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013038\"}","{\"db\":\"OMIM\",\"id\":\"612918\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"140944\"}","{\"db\":\"OMIM\",\"id\":\"612918\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CLOVE SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"612918\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CLOVES SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"171834.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"612918\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, EPIDERMAL NEVI, AND SKELETAL/SPINAL ABNORMALITIES\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528964\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552540\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558435\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000571365\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK153722\",\"ref_field\":\"public_definition\"}"],"disease_mechanism_id":"274","id":"6715","disease_mechanism":"gain of function","public_definition":"PIK3CA-associated segmental overgrowth includes disorders of brain (e.g., MCAP [megalencephaly-capillary malformation] syndrome, hemimegalencephaly); and segmental body overgrowth (e.g., CLOVES [congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies] syndrome, fibroadipose hyperplasia [FH]). Heterozygous (usually somatic mosaic) pathogenic variants of PIK3CA are causative. MCAP syndrome is characterized by the major findings of (1) megalencephaly (MEG) or hemimegalencephaly (HMEG) associated with neurologic findings of hypotonia, seizures, and mild to severe intellectual disability; and (2) cutaneous capillary malformations with focal or generalized somatic overgrowth. Additional findings can include digital anomalies (syndactyly, polydactyly), cortical malformations – most distinctively polymicrogyria (PMG); and variable connective tissue dysplasia. CLOVES (or CLOVE) syndrome and fibroadipose hyperplasia (FH) may be associated with (1) MEG or HMEG; and (2) patchy segmental overgrowth associated with skeletal anomalies, lipomatosis, vascular malformations, and epidermal nevi."}
{"type":"Disease","alternate_names":["Cloverleaf skull with thanatophoric dwarfism","THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL","Thanatophoric dysplasia with Kleeblattschaedel"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1300257","symbol":"TD2","name":"Thanatophoric dysplasia, type 2","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008547\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"Orphanet\",\"id\":\"93274\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505530\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1402\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+2/7052\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"389158007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"274","id":"4255","disease_mechanism":"gain of function","gard_id":"1402","public_definition":"Thanatophoric dysplasia (TD) is a short-limb skeletal dysplasia that is usually lethal in the perinatal period. TD is divided into subtypes: TD type I is characterized by micromelia with bowed femurs and, uncommonly, the presence of craniosynostosis of varying severity. TD type II is characterized by micromelia with straight femurs and uniform presence of moderate-to-severe craniosynostosis with cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported."}
{"type":"Disease","alternate_names":["LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE","PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE","Thanatophoric dwarfism"],"alternate_symbols":["TD"],"attribute_content":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1868678","symbol":"TD1","name":"Thanatophoric dysplasia type 1","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008546\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1860\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TD\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327813\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514902\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+1/7051\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"274","id":"4254","disease_mechanism":"gain of function","public_definition":"Thanatophoric dysplasia (TD) is a short-limb skeletal dysplasia that is usually lethal in the perinatal period. TD is divided into subtypes: TD type I is characterized by micromelia with bowed femurs and, uncommonly, the presence of craniosynostosis of varying severity. TD type II is characterized by micromelia with straight femurs and uniform presence of moderate-to-severe craniosynostosis with cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, relative macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported."}
{"type":"Disease","alternate_names":["Hereditary non-polyposis colorectal cancer, type 5"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C1833477","symbol":"HNPCC5","name":"Hereditary nonpolyposis colorectal cancer type 5","keywords":["Hereditary cancer syndrome","Neoplasm"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013710\"}","{\"db\":\"OMIM\",\"id\":\"614350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"144\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000326160\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501400\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501402\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507864\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510419\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512401\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512403\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512492\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512645\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514730\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520048\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569406\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569423\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+nonpolyposis+colorectal+cancer+type+5/8528\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","id":"10492","disease_mechanism":"loss of function"}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9","EPILEPSY, FEMALE-RESTRICTED, WITH MENTAL RETARDATION","JUBERG-HELLMAN SYNDROME","PCDH19-Related X-Linked Female-Limited Epilepsy with Mental Retardation"],"alternate_symbols":["EFMR","EIEE9"],"attribute_content":[],"medgen_id":"C1848137","symbol":"DEE9","name":"Early infantile epileptic encephalopathy 9","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010246\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101039\"}","{\"db\":\"Orphanet\",\"id\":\"2076\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300460.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 9\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPSY, FEMALE-RESTRICTED, WITH MENTAL RETARDATION\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"JUBERG-HELLMAN SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EFMR\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE9\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509008\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519167\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519196\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520051\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520980\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527938\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10806\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+9/8347\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300088\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","id":"5029","disease_mechanism":"loss of function","gard_id":"10806"}
{"type":"Disease","alternate_names":["DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1","INFANTILE SPASM SYNDROME, X-LINKED 1","OHTAHARA SYNDROME, X-LINKED","Tonic spasms with clustering, arrest of psychomotor development and hypsarrhythmia on EEG","West's syndrome","X-Linked Infantile Spasm Syndrome","X-linked infantile spasms"],"alternate_symbols":["EIEE1","IS","ISSX1"],"attribute_content":[],"medgen_id":"C3463992","symbol":"DEE1","name":"Epileptic encephalopathy, early infantile, 1","keywords":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300382.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0023\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"300382.0024\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFANTILE SPASM SYNDROME, X-LINKED 1\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OHTAHARA SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE1\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ISSX1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332436\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519156\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520051\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520980\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557944\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","id":"1617","disease_mechanism":"loss of function"}
{"type":"Disease","alternate_names":["Hereditary non-polyposis colorectal cancer, type 4"],"alternate_symbols":[],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C1838333","symbol":"HNPCC4","name":"Hereditary nonpolyposis colorectal cancer type 4","keywords":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013699\"}","{\"db\":\"OMIM\",\"id\":\"614337\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"144\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501424\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510418\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512402\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512403\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512645\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514731\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+nonpolyposis+colorectal+cancer+type+4/8527\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lynch-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614337\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","id":"10524","disease_mechanism":"loss of function","public_definition":"Lynch syndrome, often called hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited disorder that increases the risk of many types of cancer, particularly cancers of the colon (large intestine) and rectum, which are collectively referred to as colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the stomach, small intestine, liver, gallbladder ducts, urinary tract, brain, and skin. Additionally, women with this disorder have a high risk of cancer of the ovaries and lining of the uterus (endometrial cancer). Women with Lynch syndrome have a higher overall risk of developing cancer than men with the condition because of these cancers of the female reproductive system. Individuals with Lynch syndrome typically develop cancer in their forties or fifties.People with Lynch syndrome may occasionally have noncancerous (benign) growths in the colon, called colon polyps. In individuals with this disorder, colon polyps occur at a younger age but not in greater numbers than they do in the general population."}
{"type":"Disease","alternate_names":["COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 2","Hereditary non-polyposis colorectal cancer, type 2","MLH1-Related Hereditary Non-Polyposis Colon Cancer","MLH1-Related Lynch Syndrome"],"alternate_symbols":["COCA2","FCC2","HNPCC"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743612\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ASCO, 2010\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"20065170\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCRS, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11598466\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AMA/NCHPEG, 2012\",\"@Type\":\"Suggested Reading\",\"URL\":{\"$\":\"http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf\"}},{\"@Abbrev\":\"MSTF, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25070057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CAPS, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3585492\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"MSTF, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25003300\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO/ESMO, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25452455\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24310308\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Mork et al., 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25711197\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Dutch SCG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23535968\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACG, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25645574\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Mallorca group, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23408351\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"NSGC/CCA-ICC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22167527\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"SGO, 2014\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer\"},\"URL\":{\"$\":\"https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer\"}}]}","medgen_id":"C1333991","symbol":"HNPCC2","name":"Lynch syndrome II","keywords":["Hereditary cancer syndrome","Neoplasm"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012249\"}","{\"db\":\"OMIM\",\"id\":\"609310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"144\"}","{\"db\":\"OMIM\",\"id\":\"609310\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 2\"}","{\"db\":\"OMIM\",\"id\":\"609310\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"COCA2\"}","{\"db\":\"OMIM\",\"id\":\"609310\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FCC2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260599\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000317453\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000326160\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501396\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501398\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501796\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505560\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508788\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508789\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508795\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508796\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508803\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510417\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512403\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512492\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512645\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520048\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528915\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569423\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Colorectal+Cancer%2C+Hereditary+Nonpolyposis%2C+Type+2/1749\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","id":"4825","disease_mechanism":"loss of function","public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates."}
{"type":"Disease","alternate_names":["COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1","Colorectal cancer, hereditary, nonpolyposis, type 1","Hereditary non-polyposis colorectal cancer, type 1","Lynch syndrome 1","MSH2-Related Hereditary Non-Polyposis Colon Cancer","MSH2-Related Lynch Syndrome"],"alternate_symbols":["FCC1","HNPCC1"],"attribute_content":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743612\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ASCO, 2010\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"20065170\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Vasen et al., 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2740877\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ASCRS, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11598466\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987434\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AMA/NCHPEG, 2012\",\"@Type\":\"Suggested Reading\",\"URL\":{\"$\":\"http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf\"}},{\"@Abbrev\":\"MSTF, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25070057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CAPS, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3585492\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"MSTF, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25003300\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO/ESMO, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25452455\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24310308\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Mork et al., 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25711197\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Dutch SCG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23535968\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACG, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25645574\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Mallorca group, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23408351\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"NSGC/CCA-ICC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22167527\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"SGO, 2014\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer\"},\"URL\":{\"$\":\"https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer\"}}]}","medgen_id":"C2936783","symbol":"COCA1","name":"Lynch syndrome I","keywords":["Hereditary cancer syndrome","Neoplasm"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007356\"}","{\"db\":\"OMIM\",\"id\":\"120435\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"144\"}","{\"db\":\"OMIM\",\"id\":\"120435\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007356\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lynch syndrome 1\"}","{\"db\":\"OMIM\",\"id\":\"120435\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FCC1\"}","{\"db\":\"OMIM\",\"id\":\"120435\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HNPCC1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501401\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507864\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510683\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512645\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514729\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518997\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518999\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558503\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569406\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Colorectal+Cancer%2C+Hereditary+Nonpolyposis%2C+Type+1/1748\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"120435\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","id":"2582","disease_mechanism":"loss of function","public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates."}
{"type":"Disease","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"alternate_symbols":[],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"}]}"],"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C0002986","name":"Fabry disease","keywords":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"id":"1790","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","gard_id":"6400","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack."}
